联合健康(UNH.US)深陷拉美困局 拟10亿美元抛售Banmedica资产

Group 1 - UnitedHealth Group is accelerating its exit from the Latin American market, having received four non-binding offers for its Banmedica operations in Chile and Colombia, with a transaction value of approximately $1 billion [1] - The company has incurred over $8 billion in losses from its Latin American operations since initiating its exit plan in 2022, primarily due to ongoing losses from its Brazilian subsidiary, Amil, which led to a $7.1 billion impairment loss last year [1] - The new CEO, Steve Hemsley, faces significant pressure as the company's stock price plummeted 25.5% in May and has fallen 40% year-to-date, compounded by an ongoing criminal fraud investigation related to the previous CEO's management [1][2] Group 2 - The Banmedica asset has significantly depreciated since its acquisition, with insurance plan members decreasing from 2.1 million to 1.7 million and the hospital network shrinking from 13 to 7 facilities [2] - UnitedHealth Group acquired Banmedica at a high valuation of 12 times EBITDA in 2018, but continuous losses in Brazil forced the company to withdraw from the country entirely in 2023 [2] - The sale of Banmedica, advised by Brazilian investment bank BTG Pactual, is seen as a critical test for the new CEO's crisis management capabilities amid management turmoil and performance challenges [2]